Research Article|Articles in Press

Deep next-generation proteomics and network analysis reveal systemic and tissue-specific patterns in Fabry disease

Published:February 27, 2023DOI:


      Fabry disease (FD) is an X-linked lysosomal rare disease due to a deficiency of α-galactosidase A activity. The accumulation of glycosphingolipids mainly affects the kidney, heart, and central nervous system, considerably reducing life expectancy. Although the accumulation of undegraded substrate is considered the primary cause of FD, it is established that secondary dysfunctions at the cellular, tissue, and organ levels ultimately give rise to the clinical phenotype. To parse this biological complexity, a large-scale deep plasma targeted proteomic profiling has been performed. We analyzed the plasma protein profiles of FD deeply phenotyped patients (n = 55) compared to controls (n = 30) using next-generation plasma proteomics including 1463 proteins. Systems biology and machine learning approaches have been used. The analysis enabled the identification of proteomic profiles that unambiguously separated FD patients from controls (615 differentially expressed proteins, 476 upregulated, and 139 downregulated) and 365 proteins are newly reported. We observed functional remodeling of several processes, such as cytokine-mediated pathways, extracellular matrix, and vacuolar/lysosomal proteome. Using network strategies, we probed patient-specific tissue metabolic remodeling and described a robust predictive consensus protein signature including 17 proteins CD200, SPINT1, CD34, FGFR2, GRN, ERBB4, AXL, ADAM15, PTPRM, IL13RA1, NBL1, NOTCH1, VASN, ROR1, AMBP, CCN3, and HAVCR2. Our findings highlight the pro-inflammatory cytokines' involvement in FD pathogenesis along with extracellular matrix remodeling. The study shows a tissue-wide metabolic remodeling connection to plasma proteomics in FD. These results will facilitate further studies to understand the molecular mechanisms in FD to pave the way for better diagnostics and therapeutics.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Desnick RJ
        • Brady R
        • Barranger J
        • et al.
        Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
        Ann Intern Med. 2003; 138: 338-346
        • Kok K
        • Zwiers KC
        • Boot RG
        • Overkleeft HS
        • Aerts J
        • Artola M
        Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions.
        Biomolecules. 2021; 11
        • Tuttolomondo A
        • Pecoraro R
        • Simonetta I
        • Miceli S
        • Pinto A
        • Licata G.
        Anderson-Fabry disease: a multiorgan disease.
        Curr Pharm Des. 2013; 19: 5974-5996
        • Sanchez-Niño MD
        • Carpio D
        • Sanz AB
        • Ruiz-Ortega M
        • Mezzano S
        • Ortiz A.
        Lyso-Gb3 activates Notch1 in human podocytes.
        Hum Mol Genet. 2015; 24: 5720-5732
        • Schiffmann R
        • Warnock DG
        • Banikazemi M
        • et al.
        Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.
        Nephrol Dial Transplant. 2009; 24: 2102-2111
        • Weidemann F
        • Sanchez-Niño MD
        • Politei J
        • et al.
        Fibrosis: a key feature of Fabry disease with potential therapeutic implications.
        Orphanet J Rare Dis. 2013; 8: 1-12
        • Spada M
        • Pagliardini S
        • Yasuda M
        • et al.
        High incidence of later-onset Fabry disease revealed by newborn screening.
        Am J Hum Genet. 2006; 79: 31-40
        • Nowak A
        • Huynh-Do U
        • Krayenbuehl PA
        • Beuschlein F
        • Schiffmann R
        • Barbey F.
        Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.
        J Inherit Metab Dis. 2020; 43: 326-333
        • Nakao S
        • Takenaka T
        • Maeda M
        • et al.
        An atypical variant of Fabry's disease in men with left ventricular hypertrophy.
        N Engl J Mede. 1995; 333: 288-293
        • Silva CAB
        • Moura-Neto JA
        • Dos Reis MA
        • Vieira Neto OM
        • Barreto FC
        Renal manifestations of Fabry disease: a narrative review.
        Can J Kidney Health Dis. 2021; 82054358120985627
        • Echevarria L
        • Benistan K
        • Toussaint A
        • et al.
        X-chromosome inactivation in female patients with Fabry disease.
        Clin Genet. 2016; 89: 44-54
        • MacDermot K
        • Holmes A
        • Miners A.
        Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.
        J Med Genet. 2001; 38: 750-760
        • Cabukusta B
        • Neefjes J.
        Mechanisms of lysosomal positioning and movement.
        Traffic (Copenhagen, Denmark). 2018; 19: 761-769
        • Pu J
        • Guardia CM
        • Keren-Kaplan T
        • Bonifacino JS.
        Mechanisms and functions of lysosome positioning.
        J Cell Sci. 2016; 129: 4329-4339
        • Oyarzún JE
        • Lagos J
        • Vázquez MC
        • et al.
        Lysosome motility and distribution: relevance in health and disease.
        Biochim Biophys Acta Mol Basis Dis. 2019; 1865: 1076-1087
        • Tebani A
        • Afonso C
        • Marret S
        • Bekri S.
        Omics-based strategies in precision medicine: toward a paradigm shift in inborn errors of metabolism investigations.
        Int J Mol Sci. 2016; 17
        • Cigna D
        • D'Anna C
        • Zizzo C
        • et al.
        Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.
        Molecular BioSystems. 2013; 9: 1162-1168
        • Yogasundaram H
        • Nikhanj A
        • Putko BN
        • et al.
        Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction.
        J Am Heart Assoc. 2018; 7e009098
        • Matafora V
        • Cuccurullo M
        • Beneduci A
        • et al.
        Early markers of Fabry disease revealed by proteomics.
        Mol BioSyst. 2015; 11: 1543-1551
        • Manwaring V
        • Heywood WE
        • Clayton R
        • et al.
        The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients.
        J Proteome Res. 2013; 12: 2013-2021
        • Heo SH
        • Kang E
        • Kim YM
        • et al.
        Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.
        J Med Genet. 2017; 54: 771-780
        • Moore DF
        • Krokhin OV
        • Beavis RC
        • et al.
        Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.
        Proc Natl Acad Sci U S A. 2007; 104: 2873-2878
        • Birket MJ
        • Raibaud S
        • Lettieri M
        • et al.
        A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology.
        Stem Cell Rep. 2019; 13: 380-393
        • Song H-Y
        • Chien C-S
        • Yarmishyn AA
        • et al.
        Generation of GLA-knockout human embryonic stem cell lines to model autophagic dysfunction and exosome secretion in fabry disease-associated hypertrophic cardiomyopathy.
        Cells. 2019; 8: 327
        • Weidemann F
        • Beer M
        • Kralewski M
        • Siwy J
        • Kampmann C.
        Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study.
        Mol Genet Metab. 2019; 126: 169-182
        • Doykov ID
        • Heywood WE
        • Nikolaenko V
        • et al.
        Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease.
        J Med Genet. 2020; 57: 38-47
        • Tebani A
        • Mauhin W
        • Abily-Donval L
        • et al.
        A proteomics-based analysis reveals predictive biological patterns in Fabry disease.
        J Clin Med. 2020; 9
        • Rossi F
        • L'Imperio V
        • Marti H-P
        • et al.
        Proteomics for the study of new biomarkers in Fabry disease: state of the art.
        Mol Genet Metab. 2021; 132: 86-93
        • Wickham H.
        The tidyverse.
        R Package Ver. 2017; 1: 1
      1. Wickham H, Chang W, Wickham MH. Package ‘ggplot2’. Create elegant data visualisations using the grammar of graphics version. 2016;2:1-189.

      2. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:14065823. 2014.

        • Halekoh U
        • Højsgaard S.
        A kenward-roger approximation and parametric bootstrap methods for tests in linear mixed models–the R package pbkrtest.
        J Stat Softw. 2014; 59: 1-32
        • Benjamini Y
        • Hochberg Y.
        Controlling the false discovery rate: a practical and powerful approach to multiple testing.
        J R Stat Soc Series B Methodol. 1995; : 289-300
      3. McInnes L, Healy J, Melville J. Umap: uniform manifold approximation and projection for dimension reduction. arXiv preprint arXiv:180203426. 2018.

        • Thistlethwaite LR
        • Petrosyan V
        • Li X
        • Miller MJ
        • Elsea SH
        • Milosavljevic A.
        CTD: an information-theoretic algorithm to interpret sets of metabolomic and transcriptomic perturbations in the context of graphical models.
        PLoS Comput Biol. 2021; 17e1008550
        • Wright MN
        • Ziegler A
        ranger: a fast implementation of random forests for high dimensional data in C++ and R.
        J Stat Softw. 2017; 77
        • Bradley AP.
        The use of the area under the ROC curve in the evaluation of machine learning algorithms.
        Pattern Recognit. 1997; 30: 1145-1159
        • Uhlén M
        • Fagerberg L
        • Hallström BM
        • et al.
        Proteomics. Tissue-based map of the human proteome.
        Science. 2015; 3471260419
        • Kuleshov MV
        • Jones MR
        • Rouillard AD
        • et al.
        Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.
        Nucleic Acids Res. 2016; 44: W90-WW7
        • Consortium G
        • Ardlie KG
        • Deluca DS
        The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans.
        Science. 2015; 348: 648-660
        • Barbey F
        • Lidove O
        • Dormond O.
        Hypermobile Ehlers-Danlos-like syndrome in Fabry disease.
        Clin Genet. 2019; 95: 627-628
        • Barbey F
        • Qanadli SD
        • Juli C
        • et al.
        Aortic remodelling in Fabry disease.
        Eur Heart J. 2010; 31: 347-353
        • Parolo S
        • Tomasoni D
        • Bora P
        • et al.
        Reconstruction of the cytokine signaling in lysosomal storage diseases by literature mining and network analysis.
        Front Cell Dev Biol. 2021; 9
        • Slaats GG
        • Braun F
        • Hoehne M
        • et al.
        Urine-derived cells: a promising diagnostic tool in Fabry disease patients.
        Sci Rep. 2018; 8: 11042
        • Anders H-J
        • Banas B
        • Schlöndorff D.
        Signaling danger: toll-like receptors and their potential roles in kidney disease.
        J Am Soc Nephrol. 2004; 15: 854-867
        • De Francesco PN
        • Mucci JM
        • Ceci R
        • Fossati CA
        • Rozenfeld PA.
        Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide.
        Mol Genet Metab. 2013; 109: 93-99
        • Weidemann F
        • Sanchez-Niño MD
        • Politei J
        • et al.
        Fibrosis: a key feature of Fabry disease with potential therapeutic implications.
        Orphanet J Rare Dis. 2013; 8: 116
        • Karamanos NK
        • Theocharis AD
        • Piperigkou Z
        A guide to the composition and functions of the extracellular matrix.
        FEBS J. 2021; 288: 6850-6912
        • Tancini B
        • Buratta S
        • Delo F
        • et al.
        Lysosomal exocytosis: the extracellular role of an intracellular organelle.
        Membranes. 2020; 10: 406
        • Shao X
        • Taha IN
        • Clauser KR
        • Gao YT
        • Naba A.
        MatrisomeDB: the ECM-protein knowledge database.
        Nucleic Acids Res. 2020; 48: D1136-D1d44
        • Tebani A
        • Gummesson A
        • Zhong W
        • et al.
        Integration of molecular profiles in a longitudinal wellness profiling cohort.
        Nat Commun. 2020; 11: 4487